Fate Therapeutics
FATE
136 hedge funds and large institutions have $1.28B invested in Fate Therapeutics in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 38 increasing their positions, 43 reducing their positions, and 12 closing their positions.
125% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 12
20% more capital invested
Capital invested by funds: $1.07B → $1.28B (+$213M)
11% more funds holding
Funds holding: 123 → 136 (+13)
3.3% more ownership
Funds ownership: 93.59% → 96.88% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2% less call options, than puts
Call options by funds: $6.45M | Put options by funds: $6.59M
12% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$17.2M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$12.7M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$11.9M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$9.17M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$9.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$15.7M |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$5.41M |
| 3 |
AG
Artal Group
Luxembourg
|
-$5.41M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.73M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.99M |
FATE Hedge Fund Activity: Q2 2019 in Review
136 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2019, worth a combined $1.28B — up 20% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new FATE positions and 12 closed out — a net gain of 15 holders — while 38 added to existing stakes and 43 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $17.2M. The largest seller was Citadel Advisors, exiting entirely with an estimated $15.7M sold.
- 136 institutional investors held Fate Therapeutics (FATE) as of Q2 2019, up from 123 in Q1 2019.
- Funds reported $1.28B of Fate Therapeutics stock for Q2 2019, up 20% quarter-over-quarter.
- 27 funds opened new Fate Therapeutics positions in Q2 2019 and 12 closed out, a net change of +15 holders.
- The largest Fate Therapeutics buyer in Q2 2019 was Victory Capital Management, an estimated $17.2M added.
- The largest Fate Therapeutics seller in Q2 2019 was Citadel Advisors, an estimated $15.7M sold.
Based on aggregated 13F filings for Q2 2019.